Please use this identifier to cite or link to this item:
Title: Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
Issue Date: 1-Jul-2018
Citation: J. Antimicrob. Chemother..2018 Jul;(73)7:1940-1948
Abstract: Monotherapy with ritonavir-boosted PIs (PI/r) has been used to simplify treatment of HIV-1-infected patients. In previous studies raltegravir intensification evidenced ongoing viral replication and reduced T cell activation, preferentially in subjects receiving PI-based triple ART. However, data about low-level viral replication and its consequences in patients receiving PI/r monotherapy are scarce.
PMID: 29635527
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC6005067.pdf653.86 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.